Back to Home

Health, Politics and RegenMed

February 6, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Health, Politics and RegenMed

June 9, 2025

Our Broken Healthcare System Is Letting All Of Us Down

A large majority of Americans have lost faith in their healthcare system. 1  Seventy percent of physicians and medical students believe that consolidation in healthcare negatively affects patient access to high-quality, cost-effective care.  

Fundamental problems include:

  • The U.S. spends much more per capita on healthcare than any other country, yet ranks towards the bottom of developed countries in many healthcare metrics. 2
  • Over 21% of U.S. children aged 6–17 are obese.  In Japan, the number is about 3%. 3
  • 95% of medical spending comes after someone gets sick. 4
  • It is difficult to trust the recommendations of healthcare policy makers or medical “experts”.  The financial conflicts of interest are extensive and well reported. 5
  • The FDA does not know all the chemicals in our food. 6
  • Drug companies spend heavily to market more drugs, for higher prices, and for longer periods to time to Americans.  (In 2023 advertisements from drug makers accounted for half of the ad spending on five popular nightly news shows.) 7
  • A significant number of clinical trials supporting FDA drug approvals had limitations in their design or execution, affecting reproducibility.  For example, a 2012 analysis attempted to replicate 53 landmark cancer studies but succeeded in confirming the original results in only 11% of them. 8
  • 15% of hospital activity and expenditure in OECD countries is a direct result of adverse events. 9

This Is Leading To Major Political Consequences

It is not surprising that healthcare was a major – and for many Americans the major – issue in recent national elections. 10  As a result, the election outcomes will significantly impact U.S. health policy. 11

Patients and physicians alike are demanding better access to trustworthy information, a sharp reduction in unnecessary costs, and policies based on science and common sense rather than on corporate profit.  It is now a national governmental imperative to meet these demands.

RegenMed Is Well Positioned To Capitalize On These Tectonic Shifts In Healthcare Delivery

Solving these fundamental problems begins with unbiased datasets built from the bottom up by independent physicians, and not from the top down by conflicted policymakers and “experts.”  

Datasets which are clinically relevant to more patients.  Datasets which deliver on the promises of “value” and “care”, rather than merely add bureaucracy.  Datasets which are transparent to physicians and patients, and are independent of profit motive.  Datasets which reflect and evolve on the basis of legitimate medical science and well-correlated outcomes, not the opaque motives of anonymous committees.

RegenMed provides the platforms and processes to develop such datasets for any condition or protocol – efficiently and at low-cost.  Its technology and processes return to physicians and their patients the power to identify what they, and not drug companies and conflicted “experts”, believe are the diagnoses and treatment protocols most likely to lead to better and cost-effective outcomes.

And RegenMed is not stopping there.  For example, it is now working on a powerful AI layer which will enable efficient querying of any or all of its datasets.  Because of the high-quality of these datasets, we believe that such queries will provide reliable support for everyday clinical decision-making.  This is in stark contrast to the AI “hallucinations” and other artifacts of highly manipulated “big data”. 12


Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Health, Politics and RegenMed

February 6, 2025

Our Broken Healthcare System Is Letting All Of Us Down

A large majority of Americans have lost faith in their healthcare system. 1  Seventy percent of physicians and medical students believe that consolidation in healthcare negatively affects patient access to high-quality, cost-effective care.  

Fundamental problems include:

  • The U.S. spends much more per capita on healthcare than any other country, yet ranks towards the bottom of developed countries in many healthcare metrics. 2
  • Over 21% of U.S. children aged 6–17 are obese.  In Japan, the number is about 3%. 3
  • 95% of medical spending comes after someone gets sick. 4
  • It is difficult to trust the recommendations of healthcare policy makers or medical “experts”.  The financial conflicts of interest are extensive and well reported. 5
  • The FDA does not know all the chemicals in our food. 6
  • Drug companies spend heavily to market more drugs, for higher prices, and for longer periods to time to Americans.  (In 2023 advertisements from drug makers accounted for half of the ad spending on five popular nightly news shows.) 7
  • A significant number of clinical trials supporting FDA drug approvals had limitations in their design or execution, affecting reproducibility.  For example, a 2012 analysis attempted to replicate 53 landmark cancer studies but succeeded in confirming the original results in only 11% of them. 8
  • 15% of hospital activity and expenditure in OECD countries is a direct result of adverse events. 9

This Is Leading To Major Political Consequences

It is not surprising that healthcare was a major – and for many Americans the major – issue in recent national elections. 10  As a result, the election outcomes will significantly impact U.S. health policy. 11

Patients and physicians alike are demanding better access to trustworthy information, a sharp reduction in unnecessary costs, and policies based on science and common sense rather than on corporate profit.  It is now a national governmental imperative to meet these demands.

RegenMed Is Well Positioned To Capitalize On These Tectonic Shifts In Healthcare Delivery

Solving these fundamental problems begins with unbiased datasets built from the bottom up by independent physicians, and not from the top down by conflicted policymakers and “experts.”  

Datasets which are clinically relevant to more patients.  Datasets which deliver on the promises of “value” and “care”, rather than merely add bureaucracy.  Datasets which are transparent to physicians and patients, and are independent of profit motive.  Datasets which reflect and evolve on the basis of legitimate medical science and well-correlated outcomes, not the opaque motives of anonymous committees.

RegenMed provides the platforms and processes to develop such datasets for any condition or protocol – efficiently and at low-cost.  Its technology and processes return to physicians and their patients the power to identify what they, and not drug companies and conflicted “experts”, believe are the diagnoses and treatment protocols most likely to lead to better and cost-effective outcomes.

And RegenMed is not stopping there.  For example, it is now working on a powerful AI layer which will enable efficient querying of any or all of its datasets.  Because of the high-quality of these datasets, we believe that such queries will provide reliable support for everyday clinical decision-making.  This is in stark contrast to the AI “hallucinations” and other artifacts of highly manipulated “big data”. 12


1 Exclusive: More Than 70% of Americans Feel Failed by the Health Care System.Americans continue to have little faith in major institutions: Gallup.Our Healthcare System Is Broken. Can Technology Help Heal It?

2 HEALTHCARE

3 Health and Safety Figures. Japanese schoolchildren are some of the healthiest in the world. National Diabetes Statistics Report

4 What do we know about spending related to public health in the U.S. and comparable countries?

5 How to Beat Science and Influence People: Policy Makers and Propaganda in Epistemic Networks.  Industry sponsorship and research outcome.

6 More Than 10,000 Chemical Food Additives Ended Up in the U.S. Food System — Here's Why

7 RFK Jr.’s push to BAN direct-to-consumer pharma ads sparks industry anxiety and legal debate

8 Raise standards for preclinical cancer research

9 Iatrogenic Disorders: A Hidden Risk of Medical Treatment

10 The healthcare issues voters care about most, in 5 charts

11 Implications of the 2024 Election Outcome for U.S. Health Policy

12 Assessing the accuracy and quality of artificial intelligence (AI) chatbot-generated responses in making patient-specific drug-therapy and healthcare-related decisions

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.